Asia-Pacific Country-Specific Overview

2016 ◽  
pp. 151-214
Author(s):  
Christopher J. Cubbage ◽  
David J. Brooks
Keyword(s):  
Asia Pacific ◽  
Pacific Country ◽  
Asia Pacific Country ◽  
Country Specific

Coping with the COVID-19 crisis: an analysis of Twitter communication of companies

2021 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Sabrina Chong ◽  
Mahmood Momin
Keyword(s):  
New Zealand ◽  
Empirical Evidence ◽  
Coping Strategy ◽  
Asia Pacific ◽  
Content Type ◽  
Individual Level ◽  
Product Service ◽  
Pacific Country ◽  
Asia Pacific Country ◽  
Organisational Level

Purpose The purpose of this paper is to investigate how New Zealand listed companies communicate COVID-19 related concerns on Twitter during the pandemic through various coping expressions and strategies. Design/methodology/approach A thematic content analysis was conducted to analyse COVID tweets based on Gaspar et al.’s (2016) coping strategy framework. Findings Six major COVID-19-related concerns communicated by New Zealand companies were found, with product/service being the most tweeted concern. Various coping expressions and strategies were demonstrated by the companies to address these concerns. Information sharing strategy was found to be the most common coping strategy implied in all six of these concerns. Research limitations/implications The paper contributes to the scant literature in crisis communication by providing empirical evidence on how COVID-19-related concerns, coping expressions and strategies were communicated by New Zealand companies. Originality/value While extant coping research generally examined coping expressions and strategies in Western countries and at an individual level, this paper examines coping communication at organisational level in an Asia-Pacific country. As per the researchers’ knowledge, this is a novel attempt that provides empirical evidence on corporate coping communication in an Asia-Pacific country during the COVID-19 pandemic.

European ‘models’ and their implications to China: internal and external perspectives

2010 ◽  
Vol 36 (3) ◽  
pp. 755-775 ◽  
Author(s):  
XINNING SONG
Keyword(s):  
Social Development ◽  
Regional Integration ◽  
Social Power ◽  
The United States ◽  
Asia Pacific ◽  
European Studies ◽  
Peaceful Rise ◽  
External Relations ◽  
Asia Pacific Country ◽  
The Eu

AbstractEuropean Studies in China developed very rapidly in the last twenty years. The reasons for that are not only because of the smooth evolution of EU-China relations and wider and deeper economic interdependence between two economic giants, but also the relevance of the European models to China's domestic political and social development, as well as China's external relations. The article reviews the evolution of the European Studies in China and finds out that more and more research on European affairs relates to China's internal and external development. Two major aspects of the learning process are exploited further. Firstly, European models for China's domestic political and social development, including European party politics and Democratic Socialism, European social policy and social security systems, and European regional policies. Secondly, European models for China's foreign policy and external relations, including European neighbourhood policy, European concept of effective multilateralism, Europe as an example of peaceful rise, and functionalism as the way to East Asian regional integration. The EU or Europe has higher profile in China than any other Asia Pacific country. From the domestic political and social development and China's preference in international affairs we can see the silhouette of the European models. Chinese would like to learn more from Europe than the United States. It also shows clearly that the role of the EU as a social power.

scholarly journals Country and Industry-Level Performance of NASDAQ-Listed European and Asia Pacific ADRs

2018 ◽  
Vol 10 (6) ◽  
pp. 122
Author(s):  
Mark Schaub
Keyword(s):  
Asia Pacific ◽  
Industry Level ◽  
The Us ◽  
Specific Performance ◽  
Services Industry ◽  
Performance Results ◽  
Energy Companies ◽  
Level Performance ◽  
Country Specific

This study examines the 3-year performance of NASDAQ-Listed Asia Pacific and European ADRs versus the NASDAQ Index and their respective regional indexes from 1990-2010. Country specific performance results show ADRs from China, Japan and Ireland performed best versus the US and regional benchmarks. Industry-level results show the best industry performers were in the Technology Hardware & Services industry and in Energy companies.

scholarly journals Risk-Benefit and Cost-Effectiveness of Universal Iron Interventions for Public Health Control of Anemia in Young Children in 78 Countries: A Microsimulation Study

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2276-2276 ◽  
Author(s):  
Sant-Rayn Pasricha ◽  
Adrian Gheorghe ◽  
Fayrouz Ashour ◽  
Amrita Arcot ◽  
Laura E Murray-Kolb ◽  
...  
Keyword(s):  
Latin America ◽  
Cost Effectiveness ◽  
Middle East ◽  
Young Children ◽  
Burkina Faso ◽  
Cost Effective ◽  
Asia Pacific ◽  
Net Benefit ◽  
Iron Supplements ◽  
Country Specific

Abstract Almost 300 million children worldwide are anemic. Universal distribution of iron interventions (iron supplements or iron-containing multiple micronutrient powders, MNPs) to young children (e.g. <2 years of age) is a key World Health Organization recommendation to prevent anemia in low-income countries. However, concerns of iron-induced infection risk and limited effectiveness for anemia and broader child health outcomes have raised questions about whether iron interventions produce a net health benefit and are cost-effective. This has constrained implementation. Net effects likely differ in each country according to the epidemiology of anemia and infection, and local health care costs. Quality of implementation likely also affects net benefit. This means analyses must be country-specific. To help guide policymakers, we estimated country-specific net benefit-risk and cost-effectiveness of universal intervention with MNPs or iron supplements to young children. We developed a bespoke microsimulation model to estimate country-specific net Disability Adjusted Life Years (DALYs) attributable to anemia and infection in children from age 0-18 months who received MNPs, iron supplements or control from age 6-12 months. The model utilised publically available data on anemia, malaria, diarrhoea and respiratory infection epidemiology, and modified their risks according to effect sizes from the pivotal systematic reviews of randomised trials used to inform current guidelines. We next estimated corresponding cost/ DALY averted. We modeled all 78 countries (46 in Africa, 20 in Asia and 12 in Latin America) where WHO reported that anemia prevalence exceeded 40% in 2011, or where pilot iron intervention programmes have been reported to be in place. We found that MNPs and iron supplements produced a net benefit to health in all countries, though the magnitude was heterogeneous.DALYs averted/ 10,000 children in Africa ranged from 20.2 (Egypt) to 81.8 (Burkina Faso), median 49.8; in Asia/Pacific/the Middle East from 22.7 (China) to 110.1 (Yemen), median 33.4, and in Latin America from 14.1 (Ecuador) to 68.5 (Bolivia), median 26.5.The median benefit from iron supplements in Africa was 76.4 DALYs averted/10,000 children and ranged from 39.7 in Zimbabwe to 111.6 in Burkina Faso; in Asia/Pacific/Middle East the median benefit was 71.7, ranging from 36.9 in the Phillipines to 133.3 in Pakistan and 133.0 in Yemen; and in Latin America the median benefit was 59.1, ranging from 93.5 in Bolivia to 39.5 in Guatemala. The magnitude of net benefit from MNPs and iron supplements on DALYs was strongly positively associated with the prevalence of moderate anemia (e.g. for MNPs: r=0.82, P=2.3x10-20). In Africa, MNPs cost between $961-$4341/DALY averted; in Asia/Middle-East/Pacific between $844-$3975/DALY averted, and in Latin America between $1306-$6566/DALY averted. The 10 countries where MNPs are most cost-effective were Yemen ($844/DALY averted), Burkina Faso ($961), Mauritania ($1119), The Gambia ($1165), Guinea-Bissau ($1165), Senegal ($1193), Mali ($1197), Guinea ($1267), and Ghana ($1273). Suboptimal coverage markedly reduced both DALYs averted and cost-effectiveness. The severity, not just overall prevalence of anemia, should be considered when planning a programme. Optimisation of programme coverage is essential to maximise cost-effectiveness. Our results augment existing guidelines and identify locations where iron interventions have the greatest benefit and are most cost-effective. Figure Legend Caterpillar plots and regional maps demonstrating DALYs averted/ 10,000 children for A) Multiple Micronutrient Powders, and b) Iron Supplements. Disclosures No relevant conflicts of interest to declare.

scholarly journals Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region

2021 ◽  
Vol 8 ◽  
Author(s):  
Chia-Te Liao ◽  
Chun-Ting Yang ◽  
Fang-Hsiu Kuo ◽  
Mei-Chuan Lee ◽  
Wei-Ting Chang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Ejection Fraction ◽  
Standard Therapy ◽  
Cost Effective ◽  
Asia Pacific ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
The Cost ◽  
Country Specific

Background: EMPEROR-Reduced trial provides promising evidence on the efficacy of empagliflozin adding to the standard treatment in patients with heart failure and reduced ejection fraction (HFrEF). This study aimed to investigate the cost-effectiveness of add-on empagliflozin vs. standard therapy alone in HFrEF from the perspective of the Asia-Pacific healthcare systems.Methods: A Markov model was constructed to simulate HFrEF patients and to project the lifetime direct medical costs and quality-adjusted life years (QALY) of both therapies. Transitional probabilities were derived from the EMPEROR-Reduced trial. Country-specific costs and utilities were extracted from published resources. Incremental cost-effectiveness ratio (ICER) against willingness to pay (WTP) threshold was used to examine the cost-effectiveness. A series of sensitivity analyses was performed to ensure the robustness of the results.Results: The ICERs of add-on empagliflozin vs. standard therapy alone in HFrEF were US$20,508, US$24,046, US$8,846, US$53,791, US$21,543, and US$20,982 per QALY gained in Taiwan, Japan, South Korea, Singapore, Thailand, and Australia, respectively. Across these countries, the probabilities of being cost-effective for using add-on empagliflozin under the WTP threshold of 3-times country-specific gross domestic product per capita were 93.7% in Taiwan, 95.6% in Japan, 96.3% in South Korea, 94.2% Singapore, 51.9% in Thailand, and 95.9% in Australia. The probabilities were reduced when shortening the time horizon, assuming the same cardiovascular mortality for both treatments, and setting lower WTP thresholds.Conclusion: Adding empagliflozin to HFrEF treatment is expected to be a cost-effective option among the Asia-Pacific countries. The cost-effectiveness is influenced by the WTP thresholds of different countries.

Sign in / Sign up

Export Citation Format

Share Document